GlaxoSmithKline/Pozen Anticipate Mid-2007 Launch For Trexima Migraine Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
Pozen is counting on safety data from two GSK Phase IIIb trials completed after the migraine therapy’s filing to satisfy FDA’s “approvable” letter.
You may also be interested in...
Pozen/GlaxoSmithKline’s Trexima Gets Second FDA Approvable Letter
Pozen plans to pursue additional toxicity studies suggested by FDA.
Pozen/GlaxoSmithKline’s Trexima Gets Second FDA Approvable Letter
Pozen plans to pursue additional toxicity studies suggested by FDA.
GSK/Pozen To Reformat Trexima Clinical Trial Data
The firm now expects a late-June user fee date for the migraine treatment.